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Abstract
Vitamin E was recently shown to improve hepatic histology in a randomized controlled trial of pioglitazone or vitamin E for
nonalcoholic steatohepatitis (PIVENS). The current study utilized samples collected in the PIVENS trial to identify: (1) baseline
metabolomic profiles that could identify who would respond to vitamin E treatment and (2) end of treatment metabolomic
profiles reflective of histologic improvement. A comprehensive analysis of metabolomics profiles (n = 547) quantified by
mass spectrometry was performed in vitamin E responders (n = 16), vitamin E non-responders (n = 15), and placebo
responders (n = 15). At baseline, phenyl-propionic acid (Odds ratio: 29.4, p,0.01), indole-propionic acid levels (Odds ratio:
16.2, p,0.01) were directly associated with a subsequent histologic response to vitamin E treatment whereas c-
carboxyethylhydroxychroman (CEHC) levels were inversely related to histologic response. Adjusting for baseline values by
analysis of covariance, the end of treatment levels of gamma-glutamyl leucine (Fold change: 0.82, p,0.02) and gamma-
glutamyl valine (Fold change: 0.8, p,0.03) were significantly lower in vitamin E responders compared to non-responders.
The levels of gamma-glutamyl transpeptidase were not significantly different across the two groups. Subjects receiving
placebo who demonstrated a histologic improvement also demonstrated lower levels of gamma-glutamylated amino acids
(leucine, valine and isoleucine) compared to vitamin E non-responders. These data provide exploratory proof that there are
measurable differences in the metabolic profile of subjects who are likely (vs unlikely) to respond to vitamin E treatment for
NASH and in those experiencing histologic improvement (vs no improvement) on treatment and support further studies to
validate these biomarkers.
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Introduction
Nonalcoholic steatohepatitis (NASH) is a common liver disease
that is characterized by predominantly macrovesicular hepatic
steatosis, hepatocellular ballooning and lobular inflammation often
with a centrilobular distribution [1,2]. NASH affects 4–5% of the
US population and can progress to cirrhosis in up to 15% of
subjects [3,4].
Insulin resistance and oxidative stress have been implicated as
two important pathophysiologic factors that cause NASH [5–8].
The ‘‘Pioglitazone versus Vitamin E versus Placebo for the
Treatment of Nondiabetic Patients with Nonalcoholic Steatohe-
patitis’’ (PIVENS, ClinicalTrials.gov number, NCT00063622.)
was a multicenter, prospective, placebo-controlled clinical trial in
non-diabetic, non-cirrhotic subjects with histologically-active
NASH that targeted insulin resistance with pioglitazone (30 mg/
day) or oxidative stress with vitamin E (RRR- a-tocopherol
800 IU/day) [9]. In this trial, 43% of subjects receiving vitamin E
met the primary endpoint of histologic improvement compared to
19% of those receiving placebo (p,0.001) [9]. These data provide
hope for effective pharmacologic therapy for NASH.
Given that only some patients with NASH respond to vitamin E
treatment, there is a need to develop methods to identify such
individuals prior to starting therapy. Also, once treatment is
started, one has to determine if a given individual is responding to
treatment. In the PIVENS trial, the aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) declined in subjects
receiving vitamin E but did not reliably predict histologic
improvement [9]. A liver biopsy is thus needed to determine if a
given subject is responding to treatment; however, liver biopsies
are invasive, uncomfortable and occasionally associated with
clinically significant morbidity and mortality [10,11]. Therefore, a
need to develop non-invasive methods to determine the presence
of an on-treatment response exists.
Metabolomic technologies allow measurement of a multitude of
metabolites in a single plasma or tissue sample. An advantage of
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analyzing metabolomic datasets is that they can be used to identify
unique ‘‘metabolic signatures’’ of disease states in circulation.
They also provide an unbiased approach to identification of such
signatures. These considerations have led to their utilization in
biomarker development.
The objectives of this pilot exploratory study were to utilize the
plasma samples collected during the PIVENS trial to determine
whether there were significant measurable differences in the
metabolomic profiles of subjects who did or did not respond to
vitamin E treatment at baseline and at end of treatment. The goal
was to generate pilot data to provide direction for future focused
large scale studies to develop: (1) baseline predictors of histologic
response to vitamin E and (2) biomarkers indicative of histologic
response to vitamin E.
Materials and Methods
This study was approved by NASH CRN Steering Committee
(SC). It was conceived as an ancillary study to the PIVENS trial
that was performed by the NASH Clinical Research Network of
the National Institutes of Diabetes, Digestive and Kidney Diseases
(NIDDK). The protocol was approved by the ancillary studies
committee and supported via an ARRA supplement to the
institutional contract for the NASH CRN to Virginia Common-
wealth University (VCU). All participants involved in this ancillary
study provided written consent to donate serum/plasma samples
for the main study objectives and for future NASH CRN ancillary
studies. The study was considered exempt from a separate formal
institutional review because it involved retrospective analysis of
samples collected during the study. Also, the scope of the analyses
was covered under the original IRB approval for the study at all
sites. The data were analyzed by the investigators and the
manuscript prepared entirely by the investigators.
Patients and samples
The PIVENS trial was conducted by the NIDDK NASH CRN
from 2005 to 2008. The details of the study protocol and the main
results of the trial have already been published [9,12]. Briefly, non-
diabetic, non-cirrhotic adults with active NASH were enrolled.
Active NASH was defined by the presence of definite or possible
steatohepatitis with a NAFLD activity score (NAS)$5 as assessed
by the CRN site pathologist or definite steatohepatitis with a
NAS$4 as assessed by a CRN site-pathologist and another NASH
CRN pathologist [9,12]. Subjects who had a liver biopsy within
the previous six months were randomized to receive 96 weeks of
treatment with one of three treatments: (1) pioglitazone (30 mg
once a day by mouth) and vitamin E-placebo (n = 80), (2) vitamin
E (800 IU once a day by mouth) and pioglitazone-placebo (n = 84)
and (3) vitamin E-placebo and pioglitazone-placebo (n = 83). A
liver biopsy was performed after 96 weeks of treatment and the
treatments were then discontinued. 90% of subjects had both a
baseline and an end of treatment biopsy.
For the purpose of this analysis, response was defined by a
decrease in the NAS by two or more points with at least one point
improvement in hepatocyte ballooning. This is identical to the
primary endpoint of the PIVENS trial [9]. Non-response was
defined as not meeting the primary outcome of the trial, no
resolution of steatohepatitis (as determined by NASH CRN central
pathology review) and ballooning score greater than zero. This
was done to maximize the ability to identify differences in analytes
by studying the extreme ends of the spectrum of histologic
response in the trial.
Thirty six of the 84 subjects who received vitamin E met the
primary endpoint; of these, 16 subjects were selected (group 1).
This was based on the availability of paired plasma samples and
also histologic data at end of study for analysis. For the
metabolomic analyses, 15 subjects each from two control groups:
(1) vitamin E nonresponders, and (2) placebo responders. The
rationale for the former group was that it was the primary group
for comparison while that for the latter group was to assess the
specificity of potential analytes for response to vitamin E
treatment. A stratified random sampling scheme was used to
select the samples. The strata were determined by the subjects
meeting each group’s inclusion criteria and the availability of pairs
of liver biopsy tissue and fasting plasma specimens for these
subjects. For the vitamin E non-responder group, 15 of the 36
subjects who met the definition of non-response (group 2) were
randomly selected. The placebo responder group included 15 of
the 16 subjects in the placebo arm who had a histologic response
(group 3).
High-throughput metabolomic profiling
All samples were processed by Metabolon (Research Triangle
Park, NC) using GC/MS and LC/MS/MS platforms with the
methodological details summarized as follows:
Sample Preparation. Upon receipt of plasma samples,
aliquots were immediately stored at 280uC until time of analysis
when samples were extracted and prepared for analysis using
Metabolon’s standard solvent extraction method. The extracted
samples were split into equal parts for analysis on the GC/MS and
LC/MS/MS platforms. Also included were several technical
replicate samples created from a homogeneous pool containing a
small amount of all study samples (‘‘Client Matrix’’).
Liquid chromatography/Mass Spectrometry (LC/MS,
LC/MS2) analysis. The sample extract for LC/MS/MS was
split into two aliquots, dried, then reconstituted in acidic or basic
LC-compatible solvents, each of which contained 11 or more
injection standards at fixed concentrations. One aliquot was
analyzed using acidic positive ion optimized conditions and the
other using basic negative ion optimized conditions in two
independent injections using separate dedicated columns. The
MS analysis alternated between MS and data-dependent MS2
scans using dynamic exclusion.
Gas chromatography/Mass Spectrometry (GC/MS)
analysis. GC/MS sample extracts were re-dried under vacuum
desiccation for a minimum of 24 hours prior to being derivatized
under dried nitrogen using bistrimethyl-silyl-triflouroacetamide
(BSTFA). The GC column was 5% phenyl and the temperature
ramp is from 40u to 300uC in a 16 minute period. Samples were
analyzed on a Thermo-Finnigan Trace DSQ fast-scanning single-
quadrupole mass spectrometer using electron impact ionization.
The instrument was tuned and calibrated for mass resolution and
mass accuracy on a daily basis.
Metabolite identification. Compounds were identified by
comparison to library entries of purified standards or recurrent
unknown entities. Identification of known chemical entities was
based on comparison to metabolomic library entries of more than
2362 commercially available purified standards and additional
presently unknown entities were identified by virtue of their
recurrent nature.
Data normalization. Samples were analyzed over the course
of two weeks. Each run day was balanced for different sets with
samples completely randomized to avoid group block effects. For
example, a random selection of samples was made on each run
day choosing the same number from each group – say 3 vitamin E
Biomarkers of Response to Vitamin E for NASH
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responders, 3 vitamin E non-responders, and 3 placebo respond-
ers. Additionally, metabolites in each sample were normalized by
dividing respective metabolite raw area counts by their median
value for each run-day to correct for variation resulting from
instrument inter-day tuning differences. Missing values were
assumed to result from areas falling below limits of detection. As
such, missing values were imputed with the observed minimum for
each metabolite after the normalization step.
Statistical analysis
Statistical analyses were performed in the R statistical
computing environment (http://cran.r-project.org/) and SAS
(V 9.2, Cary, NC). Categorical data were analyzed by chi-
square test. Analysis of variance (ANOVA) and analysis of
covariance (ANCOVA) models were developed to analyze
continuous variables followed by Tukey post-tests for multiple
comparisons to identify specific differences between groups.
Given the small sample size which precluded meaningful
multiple comparisons analyses for the number of analytes
(n = 547), a smaller set of analytes that were significant on
univariate analysis was included in a logistic regression model
to identify those that predicted histologic outcomes of vitamin E
treatment.
Results
Study Population
A total of 46 pairs of fasting plasma samples obtained at baseline
and end of treatment were analyzed in vitamin E responders
(n = 16), vitamin E non-responders (n = 15) and placebo-respond-
ers (n = 15). Table 1 summarizes the baseline demographic,
clinical, laboratory and histologic data from these three groups.
The three groups were comparable with respect to age, gender,
race, liver enzyme values, distribution of specific features of the
metabolic syndrome, severity of underlying insulin resistance and
histologic features of NASH. Specifically, the severity of steatosis,
inflammation, hepatocyte ballooning and fibrosis were all compa-
rable across the groups.
Metabolomic analyses
Using LC/MS and GC/MS analysis, a total of 547 distinct
metabolites were identified across the analyzed plasma samples. Of
these, 314 biochemicals matched a named structure in the
reference library. The remaining 233 represented distinct chem-
ical entities, but they do not match a named biochemical in the
reference library.
A: Is the histologic response a function of enrichment of
plasma with vitamin E?. To address the possibility that the
histologic response was a direct function of the degree of
enrichment of plasma with vitamin E, the circulating levels of a-
tocopherol, c-tocopherol and c-carboxyethyl-hydroxychroman
(CEHC) a metabolite of vitamin E were measured at baseline
and at the end of treatment [13]. At baseline, the levels of a- and
c-tocopherol were similar and comparable (Figure 1). There was
a substantial enrichment of the end of treatment plasma with a-
tocopherol and c-CEHC in subjects receiving vitamin E regardless
of their histologic response status. As expected, the c-tocopherol
levels were decreased in both these groups. At baseline, CEHC
levels were lower in those who responded to vitamin E compared
to non-responders (mean: 0.77 vs 1.35 arbitrary units, P = 0.0002).
However, the end of treatment histologic response was not related
to levels of CEHC, a- or c-tocopherol. These data indicate that
the histologic response to vitamin E was not related to the plasma
levels of vitamin E or its metabolites at the end of the study and
thus the likelihood of response was not related to compliance
alone.
B: Identification of predictors of histologic response to
vitamin E prior to therapy. This was assessed by comparison
of the metabolomic profiles of vitamin E responders vs non-
responders at baseline prior to initiation of therapy. Analytes that
were significantly different at baseline in responders vs nonre-
sponders were fitted to a logistic regression model to identify those
that predicted vitamin_E related histologic response. The signif-
icant metabolites identified are listed in Table 2. Phenyl-
propionic acid and Indole-propionic acid, two intestinal micro-
biome-derived metabolites [14] were significantly associated with a
subsequent histologic response to vitamin E. The levels of
asparagine also predicted future response to vitamin E. Converse-
ly, the pre-treatment levels of c-CEHC a metabolite of vitamin E
was inversely associated with response to vitamin E therapy. The
levels of c-palmitoylglycerophosphoethanolamine and myristoleate
were also inversely associated with histologic improvement after
vitamin E administration.
C: Differential changes in the metabolome of responders
vs non-responders identified glutathione metabolites as
potential biomarkers of response. A total of 11 metabolites
were differentially expressed between vitamin E responders and
vitamin E non-responders at the end of treatment. Two of these
were gamma-glutamyl leucine and gamma-glutamyl valine. At
baseline, the levels of these compounds were comparable in the
two groups. Adjusting for baseline values by ANCOVA, the end of
treatment values of these metabolites were significantly lower in
vitamin E responders compared to non-responders (Table 3). The
levels of other metabolites except sphingosine (see below) did not
reach significance when adjusted for baseline values. Thus, a
histologic response to vitamin E was associated with lower
circulating levels of gamma-glutamylated amino acids, indicative
of decreased glutathione turnover and improved systemic oxida-
tive stress [14,15].
D: Relationship of c-glutamyl peptidase (GGT) levels to
histologic response. Under conditions of oxidative stress,
intracellular glutathione turnover is increased [16–18]. This
activates the enzyme c-glutamyl transpeptidase (GGT) to cleave
extracellular glutathione to release gamma-glutamylated amino
acids which are taken up for intracellular glutathione reconstitu-
tion [16,18]. Given the relationship of gamma-glutamylated
amino acid levels to histologic improvement, we tested the
hypothesis that the GGT levels could be used as a surrogate
measure of histologic response. The mean GGT levels at baseline
were 60 IU/l and 47 IU/l respectively for vitamin E responders vs
non-responders (Figure 2). While those who had a histologic
response and a greater decrease compared to non-responders
(mean decrease 21641 IU vs 9619 IU, non-significant) this did
not reach statistical significance.
E. Sphingosine metabolites and response to vitamin E
treatment. A third metabolite whose levels were significantly
different in vitamin E responders vs non-responders at end of
treatment was sphingosine (Table 3). The levels of sphingosine
were comparable amongst the two groups at baseline. However,
adjusting for baseline levels the end of treatment levels of
sphingosine were lower in those with a vitamin E response
compared with vitamin E non-responders. TNF-a is a significant
predictor for end of treatment sphingosine level after adjusting for
baseline sphingosine and treatment group. TNF-a activates
sphingomyelinase to release sphingosine. The end of treatment
Biomarkers of Response to Vitamin E for NASH
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TNF-a is significantly lower in vitamin E responders vs non-
responders (Figure 3). Other sphingosine-associated metabolites
were not significantly different.
F: Specificity of metabolic markers of histologic response
for vitamin E. This was evaluated from the metabolomic
profile of subjects receiving placebo who also achieved
histologic improvement (Table 3). Adjusting for baseline
values by using ANCOVA, placebo-responders also demon-
strated levels of gamma-glutamyl leucine and gamma-glutamyl
valine that were comparable to vitamin E responders and lower
than those seen in vitamin E non-responders. In addition,
placebo responders also had a significant decrease in the levels
of gamma-glutamyl isoleucine (0.67, p = 0.01) and sphingosine
(fold change: 0.63, p = 0.02). In vitamin E responders, a trend
for decreased levels for gamma-glutamyl isoleucine was seen
but did not reach significance. When combined with vitamin E
treated subjects, gamma-glutamyl leucine and gamma-glutamyl
valine remained significant predictors of on-treatment response.
These data indicate that histologic response in both those on
placebo and in vitamin E responders was associated with a
decrease in markers of oxidative stress and intracellular
glutathione turnover.
Discussion
NASH is closely associated with the metabolic syndrome and
its related array of biologic disturbances that produces changes in
systemic and hepatic metabolism, oxidative stress, apoptosis,
Table 1. Baseline characteristics of study population.
Characteristic Vit.E responder(n =16)
Vit.E non-responder
(n=15)
Placebo responder
(n=15) p-value
Demographic factors
age(yr) 43.6612.9 48.166.4 44.468.3 ns
female sex (%) 62.5 73.3 46.7 ns
Race or ethnic group (%)
non-hispanic white 53.3 73.3 60 ns
non-hispanic other 20 13.3 20
any Hispanic 26.7 13.3 20
Serum biochemical levels
Alanine aminotransferase (U/liter) 97645 106659 73640 ns
Aspartate aminotransferase (U/liter) 69639 70642 46623 ns
c-Glutamyltransferase (U/liter) 60642 47623 67673 ns
Alkaline phosphatase (U/liter) 72617 92628 80625 ns
Total bilirubin (mg/dl) 0.8760.37 0.7260.31 0.7760.45 ns
Lipids
Triglycerides (mg/dl) 1426103 1976110 156679 ns
Cholesterol (mg/dl)
Total 189649 211625 202635 ns
High-density lipoprotein 43613 4268 4469 ns
Low-density lipoprotein 125635 135623 129631 ns
Metabolic factors
Fasting serum glucose (mg/dl) 95613 95615 96616 ns
Weight (kg) 93625 96618 95619 ns
Body-mass index 3266 3465 3366 ns
Waist circumference (cm) 109614 108614 106614 ns
Liver histologic findings
Total NAFLD activity score 5.761.4 5.260.8 5.261.3 ns
Steatosis 2.160.8 1.760.8 1.860.7 ns
Lobular inflammation 2.160.7 1.96.0.6 1.860.6 ns
Hepatocellular ballooning 1.560.5 1.660.5 1.560.5 ns
Fibrosis scores (%)
Stage 0 or 1 43.7% 66.7% 53.3% ns
Stage 2 31.3% 26.6% 26.7%
Stage 3 25% 6.7% 20%
Stage 4 0 0 0
doi:10.1371/journal.pone.0044106.t001
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inflammatory and fibrotic pathways. These produce changes in
the production and utilization of many metabolites in the liver
and indeed systemically. The circulating levels of these metab-
olites reflect an integration of such changes at a systemic level
with those in the liver and provide an opportunity to define the
‘‘metabolic signature’’ of NASH at various stages of its natural
history and following pharmacologic intervention. The use of
such technologies for both type 0 (to identify disease states) and
type 1 (to identify therapeutic responses) biomarker (US NIH
Biomarkers Definition Group) development is considered a
priority in the ‘‘liver action plan’’ for the National Institutes of
Health [19,20]. This exploratory study provides initial evidence
that there are measureable differences in the plasma metabolomic
profile of (1) thosewho will or will not respond to vitamin E
treatment in the future, and (2) those who are improving vs those
who are not.
The possibility of avoiding a liver biopsy to assess treatment
response is similarly exciting because it removes a barrier towards
widespread translation of the results of the PIVENS trial to clinical
practice. The realization of this possibility will require confirma-
tion of our data in large scale appropriately designed prospective
studies. In this study, we chose the two extreme histologic response
phenotypes for comparison i.e. those who met a very robust and
tight definition of histologic response and those who had no
significant changes in any of the histologic parameters of NASH to
provide proof of concept that there are differences in their
metabolomic profiles. The metabolomic profiles of those who have
some improvement of specific histologic parameters without
meeting the primary outcome endpoint of the PIVENS trial are
unknown. The potential impact of such ‘‘partial histologic
responders’’ on the diagnostic utility of any model developed to
assess treatment response to vitamin E also needs additional
evaluation.
A key aspect of biomarker development relates to potential
pitfalls in the methodology used. Specifically, both biases in
treatment assignment and the sequence of sample loading for
processing can be a source for potential bias in the data output
[9,12]. These data were collected in the context of the PIVENS
trial and the population of subjects assigned to treatment with
vitamin E was relatively homogeneous [9]. In our study, special
efforts were taken (see methods section) to avoid analytic biases.
The study of metabolomic signatures of subjects on treatment
with vitamin E also provides some insights in to the potential
effects of vitamin E treatment on the biology of NASH. It is
interesting to note that, in an unbiased evaluation of the
metabolome, the principal metabolites that distinguished vitamin
E responders and non-responders were related to glutathione
metabolism. Glutathione is a principal intracellular anti-oxidant
and helps maintain redox balance, especially in the liver
[14,15,21]. Gamma-glutamylated amino acids are established
Figure 1. The circulating levels of a-tocopherol, c-tocopherol and c-carboxyethylhydroxychroman (CEHC) a metabolite of vitamin E
are shown at baseline (panel A) and at end of treatment (panel B) for subjects receiving vitamin E who either met histologic criteria
for a response (responders) or met the criteria for non-response. CEHC was significantly lower at baseline in vitamin E treatment responders.
The levels of a-, and c-tocopherols were similar in the two groups at baseline. There was a similar enrichment of a-tocopherol in both responders and
non-responders. Conversely, there was a relative de-enrichment of c-tocopherol in both groups. These data indicate that the histologic response to
vitamin E was not a simple response of the amount of vitamin E enrichment of plasma.
doi:10.1371/journal.pone.0044106.g001
Table 2. Baseline predictors for vitamin E responders.
Metabolites
Odds Ratio (OR) vs non-
responders p-value 95% CI
2-palmitoylglycerophosphoethanolamine 0.08 0.03 0.01–0.56
myristoleate (14:1n5) 0.04 0.02 0.002–0.64
gamma-CEHC 0.11 0.02 0.01–0.995
Asparagines 20.2 0.01 1.2–338.6
indolepropionate 16.2 0.01 1.45–180.7
3-phenylpropionate (hydrocinnamate) 29.4 0.01 1.23–707.0
Simple logistic regression models were fitted here due to small sample size, significance level is set at a,0.05.
doi:10.1371/journal.pone.0044106.t002
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markers of oxidative stress and reflect glutathione turnover [16].
The drop in such amino acids in both those where NASH
improves on vitamin E treatment or spontaneously (on placebo)
indicates that histologic improvement in NASH under both these
conditions is associated with decreased oxidative stress and
glutathione turnover. Whether the improvement in oxidative
stress improves NASH or vice versa now awaits experimental
elucidation.
Sphingosine is released by the action of the tumor necrosis
factor-a-sensitive enzyme sphingomyelinase on cell membrane-
bound sphingomyelin [22–24]. While there is a relative abundance
of literature of the potential role of sphingosine-1-phosphate in the
metabolic syndrome and its biologic effects, very little is known
about the regulation of sphingosine in circulation or its biologic
implications. We hypothesize that the novel finding of decreased
sphingosine in vitamin E responders reflects decreased TNF-a
activity in responders and hope that these findings will provide
impetus to future studies of the sphingosine-ceramide pathway in
NASH. This is supported by a direct relationship between TNF-a
and sphingosine levels in subjects receiving vitamin E; the
dependence of sphingosine levels on TNF-a needs to be
experimentally verified.
It is also intriguing to note that two of the metabolites (indole-
propionic acid and phenyl-propionic acid) that predicted future
response to vitamin E therapy can be derived from intestinal
microbiota [25]. The tryptophan- and indole-derived compounds
have well-established free-radical scavenger and mitochondrial
protective properties [26]. These novel findings open the
possibility that vitamin E response may depend on the presence
of these specific microbiome-derived metabolites or changes in
specific microbiota to boost the net anti-oxidant effect achieved.
The principal limitations of this study are the small sample size
and the lack of liver tissue for metabolomic analysis which prevent
generation of definitive data about biomarkers for response to
vitamin E and pathophysiological data about the role of oxidative
stress in NASH. However, it is important to emphasize the
exploratory nature of this study and that the primary objective was
to generate pilot ‘‘proof of principle’’ data to provide direction and
support for focused yet large-scale studies to develop biomarkers
for response to vitamin E for NASH. By providing such focused
data, one may avoid the need for prohibitively expensive large
scale full metabolomics profiling to identify such biomarkers.
In summary, this exploratory study provides pilot investigation
that there are differences in the circulating profiles of subjects with
NASH who will or will not respond to vitamin E treatment and
amongst those who are responding to treatment vs those who are
not. They also provide several novel findings and insights about
the mechanisms of action of vitamin E in NASH which now
require further elucidation in specific hypothesis-driven studies.
While much work needs to be done to translate these data in to
models for personalized clinical care of patients with NASH, this
study provides a first step in this direction with respect to the use of
vitamin E for NASH.
Table 3. End of treatment vitamin E and placebo response biomarkers.
Vitamin E responder vs Vitamin E non-responder Metabolites Fold Change p-value
Gammaglutamylleucine 0.82 0.02
Gammaglutamylvaline 0.80 0.03
Sphingosine 0.64 0.02
Placebo responder vs Vitamin E non-responder Metabolites Fold Change p-value
Gammaglutamylisoleucine 0.67 0.01
Gammaglutamyleucine 0.85 0.05
Sphingosine 0.63 0.02
Gammaglutamyvaline 0.81 0.07
ANCOVA models adjusting for baseline metabolites level with Tukey Method for multiple comparison.
doi:10.1371/journal.pone.0044106.t003
Figure 2. Baseline and end of treatment levels of gamma glutamyl transpeptidase in vitamin E responders and non-responders are
shown. The baseline values in both groups are comparable. At the end of treatment, the levels decreased in both groups but the degree of decrease
was greater in vitamin E responders. This however was only a trend and not statistically significant.
doi:10.1371/journal.pone.0044106.g002
Biomarkers of Response to Vitamin E for NASH
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